Journal Article
. 2017 Apr;164(2).
doi: 10.1007/s10549-017-4266-9.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

A Sheri 1 I E Smith 2 M Hills 3 R L Jones 2 S R Johnston 2 M Dowsett 2 
  • PMID: 28447240
  •     23 References
  •     2 citations


Aims: To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone.

Methods: 113 patients with ER+ primary breast cancer treated with neo-adjuvant chemotherapy at the Royal Marsden Hospital between 2002 and 2010 were included in the study. Pathologic assessment of the excision specimen was made for residual disease. IHC4 was determined on pre-treatment core biopsies, blinded to clinical outcome, by immunohistochemistry using quantitative scoring of ER (H-score), PgR (%) and Ki67 (%). Determination of HER2 status was made by immunohistochemistry and fluorescent in situ hybridization for 2+ cases. IHC4 and Ki67 scores were tested for their association with pathological complete response (pCR) rate and residual cancer burden (RCB) score.

Results: 18 (16%) of the 113 patients and 8 (9%) of the 88 HER2-ve cases achieved pCR. Ki67 and IHC4 score were both positively associated with achievement of pCR (P < 10-7 and P < 10-9, respectively) and RCB0+1 (P < 10-5 and P < 10-9, respectively) following neo-adjuvant chemotherapy in all patients. Rates of pCR+RCB1 were 45 and 66% in the highest quartiles of Ki67 and IHC4 scores, respectively. In ER+HER2-ve cases, pCR+RCB1 rates were 35% and in the highest quartile of both Ki67 and IHC4. There were no pCRs in the lower half of IHC4 or Ki67 scores.

Conclusions: IHC4 was strongly predictive of pCR or near pCR in ER+ breast cancers following neo-adjuvant chemotherapy. Ki67 was an important component of this predictive ability, but was not as predictive as IHC4.

Keywords: Breast cancer; IHC4; Ki67; Neo-adjuvant chemotherapy.

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Frédérique Penault-Llorca, Fabrice André, +11 authors, Henri Roché.
J Clin Oncol, 2009 Apr 22; 27(17). PMID: 19380452
EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
François Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum.
Cancer Lett, 2014 Sep 15; 355(1). PMID: 25218596
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, +11 authors, Lajos Pusztai.
J Clin Oncol, 2007 Sep 06; 25(28). PMID: 17785706
Highly Cited.
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.
A Sheri, I E Smith, +8 authors, M Dowsett.
Ann Oncol, 2014 Nov 02; 26(1). PMID: 25361988
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.
M Colleoni, I Minchella, +10 authors, A Goldhirsch.
Ann Oncol, 2000 Oct 19; 11(8). PMID: 11038046
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, +2 authors, Karen A Gelmon.
Lancet Oncol, 2010 Feb 16; 11(2). PMID: 20152769
Highly Cited. Review.
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Aleix Prat, Patricia Galván, +14 authors, Emilio Alba.
Clin Cancer Res, 2015 Jul 15; 22(3). PMID: 26152740
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Giuseppe Viale, Meredith M Regan, +16 authors, Alan S Coates.
J Clin Oncol, 2008 Mar 20; 26(9). PMID: 18349391
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
B Yeo, L Zabaglo, +3 authors, M Dowsett.
Br J Cancer, 2015 Jul 17; 113(3). PMID: 26180920    Free PMC article.
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.
A E Ring, I E Smith, +2 authors, S R Lakhani.
Br J Cancer, 2004 Nov 24; 91(12). PMID: 15558072    Free PMC article.
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Cornelia Liedtke, Christos Hatzis, +8 authors, Lajos Pusztai.
J Clin Oncol, 2009 Apr 15; 27(19). PMID: 19364972    Free PMC article.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, +11 authors, Charles Vogel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204205    Free PMC article.
Highly Cited.
Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Andrew Dodson, Lila Zabaglo, +3 authors, Mitch Dowsett.
J Clin Pathol, 2015 Aug 19; 69(2). PMID: 26281860
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, +13 authors, S E Singletary.
J Clin Oncol, 1999 Mar 18; 17(2). PMID: 10080586
Highly Cited.
Reporting results of cancer treatment.
A B Miller, B Hoogstraten, M Staquet, A Winkler.
Cancer, 1981 Jan 01; 47(1). PMID: 7459811
Highly Cited.
International Web-based consultation on priorities for translational breast cancer research.
Mitch Dowsett, Aron Goldhirsch, +3 authors, Giuseppe Viale.
Breast Cancer Res, 2007 Nov 24; 9(6). PMID: 18034879    Free PMC article.
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
S Barton, L Zabaglo, +6 authors, M Dowsett.
Br J Cancer, 2012 Apr 26; 106(11). PMID: 22531639    Free PMC article.
Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.
Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel.
Int J Breast Cancer, 2018 Aug 17; 2018. PMID: 30112216    Free PMC article.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Rohit Bhargava, Nicole N Esposito, +11 authors, David J Dabbs.
Mod Pathol, 2020 Jul 15; 34(1). PMID: 32661297